泽璟制药：注射用ZG005与注射用ZGGS18联用的临床试验申请获得FDA批准

Core Viewpoint - ZaiJing Pharmaceutical (688266.SH) announced the approval of its clinical trial application for the combination of injectable ZG005 and ZGGS18 by the U.S. Food and Drug Administration for the treatment of advanced solid tumors [1] Group 1 - Injectable ZG005 is expected to be used for the treatment of various solid tumors and is one of the first drugs globally to enter clinical research for the same target [1] - Currently, there are no similar mechanism drugs approved for marketing worldwide [1] - Injectable ZGGS18 is anticipated to become an innovative biological product for the treatment of solid tumors [1] Group 2 - The approval of this clinical trial will not have a significant impact on the company's recent performance [1]